[go: up one dir, main page]

WO2024030956A3 - Cd39-specific binding agents and methods of using the same - Google Patents

Cd39-specific binding agents and methods of using the same Download PDF

Info

Publication number
WO2024030956A3
WO2024030956A3 PCT/US2023/071512 US2023071512W WO2024030956A3 WO 2024030956 A3 WO2024030956 A3 WO 2024030956A3 US 2023071512 W US2023071512 W US 2023071512W WO 2024030956 A3 WO2024030956 A3 WO 2024030956A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding agents
methods
same
specific binding
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/071512
Other languages
French (fr)
Other versions
WO2024030956A2 (en
Inventor
Courtney Crane
Susan JULIEN
Su Jung YANG
Kristine SWIDEREK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mozart Therapeutics Inc
Original Assignee
Mozart Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mozart Therapeutics Inc filed Critical Mozart Therapeutics Inc
Publication of WO2024030956A2 publication Critical patent/WO2024030956A2/en
Publication of WO2024030956A3 publication Critical patent/WO2024030956A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Binding agents (e.g., antibodies or antibody binding fragments thereof) that specifically bind to CD39 expressed on CD8+ T regulatory cells, and their use in the treatment of diseases or disorders, such as an inflammatory disease or an autoimmune disease, are provided.
PCT/US2023/071512 2022-08-03 2023-08-02 Cd39-specific binding agents and methods of using the same Ceased WO2024030956A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263370353P 2022-08-03 2022-08-03
US63/370,353 2022-08-03
US202263380879P 2022-10-25 2022-10-25
US63/380,879 2022-10-25

Publications (2)

Publication Number Publication Date
WO2024030956A2 WO2024030956A2 (en) 2024-02-08
WO2024030956A3 true WO2024030956A3 (en) 2024-04-11

Family

ID=87800863

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/071512 Ceased WO2024030956A2 (en) 2022-08-03 2023-08-02 Cd39-specific binding agents and methods of using the same

Country Status (1)

Country Link
WO (1) WO2024030956A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024275646A1 (en) * 2023-05-24 2025-11-13 Mozart Therapeutics, Inc. Cd8-specific binding proteins and methods of using the same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2737907A2 (en) * 2007-05-07 2014-06-04 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2016120789A1 (en) * 2015-01-28 2016-08-04 Glaxosmithkline Intellectual Property Development Limited Agonistic icos binding proteins
WO2019027935A1 (en) * 2017-07-31 2019-02-07 Tizona Therapeutics Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
WO2021037037A1 (en) * 2019-08-27 2021-03-04 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-cd39 antibodies
WO2021209356A1 (en) * 2020-04-14 2021-10-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
EP0247091B1 (en) 1985-11-01 1993-09-29 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE19742706B4 (en) 1997-09-26 2013-07-25 Pieris Proteolab Ag lipocalin muteins
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20030167531A1 (en) 1998-07-10 2003-09-04 Russell Douglas A. Expression and purification of bioactive, authentic polypeptides from plants
US6512162B2 (en) 1998-07-10 2003-01-28 Calgene Llc Expression of eukaryotic peptides in plant plastids
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
AU1573601A (en) 1999-10-21 2001-04-30 Monsanto Company Post-translational modification of recombinant proteins produced in plants
MXPA02010011A (en) 2000-04-11 2003-04-25 Genentech Inc Multivalent antibodies and uses therefor.
AU2002218166A1 (en) 2000-09-08 2002-03-22 Universitat Zurich Collections of repeat proteins comprising repeat modules
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
EP1629012B1 (en) 2003-05-31 2018-11-28 Amgen Research (Munich) GmbH Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
ES2393555T3 (en) 2003-10-22 2012-12-26 Keck Graduate Institute Methods for the synthesis of hetero-multimeric polypeptides in yeasts using a haploid mating strategy.
ATE459374T1 (en) 2003-11-28 2010-03-15 Micromet Ag COMPOSITIONS CONTAINING POLYPEPTIDES
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
CA2561533C (en) 2004-04-13 2015-06-16 Yvo Graus Anti-p-selectin antibodies
TWI380996B (en) 2004-09-17 2013-01-01 Hoffmann La Roche Anti-ox40l antibodies
SG2014010029A (en) 2005-08-19 2014-08-28 Abbott Lab Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP3178850B1 (en) 2005-10-11 2021-01-13 Amgen Research (Munich) GmbH Compositions comprising cross-species-specific antibodies and uses thereof
EP2059533B1 (en) 2006-08-30 2012-11-14 Genentech, Inc. Multispecific antibodies
KR101773696B1 (en) 2007-04-03 2017-08-31 암젠 리서치 (뮌헨) 게엠베하 Cross-species-specific cd3-epsilon binding domain
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
MX350962B (en) 2008-01-07 2017-09-27 Amgen Inc Method for making antibody fc-heterodimeric molecules using electrostatic steering effects.
HUE032025T2 (en) 2008-01-31 2017-08-28 Inserm - Inst Nat De La Sante Et De La Rech Medicale Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
ES2684602T3 (en) 2010-12-22 2018-10-03 Orega Biotech Antibodies against human CD39 and use thereof
CN105949313B (en) 2011-03-29 2021-06-15 罗切格利卡特公司 Antibody Fc variants
ES2659764T3 (en) 2011-08-23 2018-03-19 Roche Glycart Ag Bispecific T-cell activating antigen binding molecules
EP4063858A1 (en) 2016-03-14 2022-09-28 Biogen International Neuroscience GmbH Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteins
EP3665195A4 (en) 2017-08-11 2021-05-19 Research Development Foundation MODIFIED FC ANTIBODY VARIANTS FOR IMPROVED SERIC HALF-LIFE

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2737907A2 (en) * 2007-05-07 2014-06-04 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2016120789A1 (en) * 2015-01-28 2016-08-04 Glaxosmithkline Intellectual Property Development Limited Agonistic icos binding proteins
WO2019027935A1 (en) * 2017-07-31 2019-02-07 Tizona Therapeutics Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
WO2021037037A1 (en) * 2019-08-27 2021-03-04 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-cd39 antibodies
WO2021209356A1 (en) * 2020-04-14 2021-10-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CINZIA SOLINAS ET AL: "The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy", ESMO OPEN, vol. 5, no. 1, 1 January 2020 (2020-01-01), pages e000544, XP055735963, DOI: 10.1136/esmoopen-2019-000544 *
HU DAN ET AL: "CD8+ Tregs kill pathogenic cells to avert autoimmunity", TRENDS IN IMMUNOLOGY, vol. 43, no. 6, 1 June 2022 (2022-06-01), GB, pages 415 - 416, XP093112296, ISSN: 1471-4906, Retrieved from the Internet <URL:https://www.cell.com/trends/immunology/pdf/S1471-4906(22)00092-8.pdf> DOI: 10.1016/j.it.2022.04.006 *
IVAN PERROT ET AL: "Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies", CELL REPORTS, vol. 27, no. 8, 1 May 2019 (2019-05-01), US, pages 2411 - 2425.e9, XP055610275, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2019.04.091 *
LI JING ET AL: "KIR + CD8 + T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19", SCIENCE, vol. 376, no. 6590, 15 April 2022 (2022-04-15), US, XP093112109, ISSN: 0036-8075, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995031/pdf/science.abi9591.pdf> DOI: 10.1126/science.abi9591 *
SIMPSON TYLER R ET AL: "Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS)", CURRENT OPINION IN IMMUNOLOGY, vol. 22, no. 3, 1 June 2010 (2010-06-01), GB, pages 326 - 332, XP093112300, ISSN: 0952-7915, Retrieved from the Internet <URL:https://pdf.sciencedirectassets.com/272032/1-s2.0-S0952791510X00048/1-s2.0-S0952791510000026/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEOX//////////wEaCXVzLWVhc3QtMSJHMEUCIEcy1LN4tWYuGxXwwgfynwykhNLiYCb3VIRO+NYA1xHcAiEAoSl96oP6sTHWLTpkRYR9tFfvr0xDv1jn1hny2PXfF0cqsgUIXhAFGgwwNTkwMDM1NDY4NjUiDI0Q7> DOI: 10.1016/j.coi.2010.01.001 *
TIMPERI ELEONORA ET AL: "CD39 Regulation and Functions in T Cells", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 22, no. 15, 28 July 2021 (2021-07-28), Basel, CH, pages 8068, XP093112249, ISSN: 1422-0067, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8348030/pdf/ijms-22-08068.pdf> DOI: 10.3390/ijms22158068 *
VIEYRA-LOBATO MARTHA R. ET AL: "Description of CD8 + Regulatory T Lymphocytes and Their Specific Intervention in Graft-versus-Host and Infectious Diseases, Autoimmunity, and Cancer", JOURNAL OF IMMUNOLOGY RESEARCH, vol. 2018, 5 August 2018 (2018-08-05), US, pages 1 - 16, XP093112250, ISSN: 2314-8861, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098849/pdf/JIR2018-3758713.pdf> DOI: 10.1155/2018/3758713 *
ZHANG ZHENQING ET AL.: "Abstract 5528: A highly potent anti-CD39 biparatopic antibody and bispecific for cancer therapy | Cancer Research | American Association for Cancer Research", CANCER RESEARCH, 15 June 2022 (2022-06-15), XP093108860, Retrieved from the Internet <URL:https://aacrjournals.org/cancerres/article/82/12_Supplement/5528/700582/Abstract-5528-A-highly-potent-anti-CD39> *

Also Published As

Publication number Publication date
WO2024030956A2 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
EP1603949B8 (en) Antibodies against human il-21 receptor and uses therefor
MY146664A (en) Antibodies against human il-22 and uses therefor
WO2007100643A3 (en) Methods of using antibodies against human il-22
WO2022081718A8 (en) Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
IL173477A (en) Multispecific antibody comprising binding arms which bind to two different antigens on the same target cell and its use in the preparation of a pharmaceutical composition
WO2018226580A3 (en) Antibodies that specifically bind pd-1 and methods of use
WO2021055253A3 (en) Anti-tnfr2 antibodies and methods of use
NO20073063L (en) Monoclonal antibody to NKG2A
WO2005110474A3 (en) HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
MY160590A (en) Cd127 binding proteins
WO2006077471A3 (en) Combining therapies targeting multiple toll-like receptors and use thereof
EA201000424A1 (en) ANTIBODIES TO IL-23
WO2007084775A3 (en) Compositions and methods for modulation of suppressor t cell activation
WO2004078098A3 (en) Peptides associated with hla-dr mhc class ii molecules involved in autoimmune diseases
WO2020128446A3 (en) Anti-btla antibodies
WO2020180712A8 (en) Anti-tnfr2 antibodies and uses thereof
WO2020185796A9 (en) High avidity wt1 t cell receptors and uses thereof
WO2024178202A3 (en) Anti-cd3 antibodies and methods for their use
WO2024030956A3 (en) Cd39-specific binding agents and methods of using the same
MY149448A (en) Interleukin-21 receptor binding proteins
NZ778810A (en) Antibodies targeting c5ar
WO2021263167A3 (en) Il-10 muteins and fusion proteins thereof
AU2024275646A1 (en) Cd8-specific binding proteins and methods of using the same
WO2022197914A3 (en) Stem cell factor antibodies and methods of use thereof
MX2021008453A (en) Formulations of antibodies that bind human cd137 and uses thereof.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23761376

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 23761376

Country of ref document: EP

Kind code of ref document: A2